The Quantellect read.As of Nov 19, 2026, 5 active firms cover MiMedx Group Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $6.00 to $10.00, a moderate spread. The average target of $8.40 sits 164% above the current $3.18. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.01 next quarter toward $0.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.40
+164.2% upside
Average target across 5 active firms as of Nov 19, 2026 vs $3.18 current
Highest Target$10.00
Average Target$8.40
Lowest Target$6.00
Detailed analyst forecasts for MDXG
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate MDXG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MDXG EPS & revenue forecast
EPS · NEXT QUARTER
$0.01
Range $0.01 – $0.01 · 2 analysts · -120% YoY
Next period, 2 analysts expect MiMedx Group Inc to earn $0.01 a share (range $0.01 – $0.01), versus $-0.05 a year earlier. Full-year consensus is $-0.10, growing to $0.03 the year after.
REVENUE · NEXT QUARTER
$64.5M
Range $62.9M – $65.5M · 2 analysts · +9% YoY
Revenue is expected to reach $64.5M (range $62.9M – $65.5M), +9.3% year-over-year. Full-year consensus is $251.8M, rising to $284.9M next year.
Top analysts covering MiMedx Group Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDXG.
#1
Chase Knickerbocker
Craig-Hallum · Rank #17
Buy
$8.00+151.6% to target
Overall win rate
61%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Buy
$10.00+214.5% to target
Overall win rate
45%
+ Follow
#3
Sarah James
Cantor Fitzgerald · Rank #159
Buy
$8.00+151.6% to target
Overall win rate
37%
+ Follow
#4
Ross Osborn
Cantor Fitzgerald · Rank #238
Buy
$12.00+277.4% to target
Overall win rate
34%
+ Follow
#5
David Turkaly
JMP Securities · Rank #453
Buy
$6.00+88.7% to target
Overall win rate
35%
+ Follow
MDXG stock forecast FAQ
What is MDXG's average 12-month price target?+
The 5 active firms with a live target average $8.40 for MiMedx Group Inc over the next 12 months, ranging from a $10.00 high to a $6.00 low, as of Nov 19, 2026.
Is MDXG stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MDXG?+
The Street-high target is $10.00 (Lake Street), and the Street-low is $6.00 (Citizens). The average of all 5 active-firm targets is $8.40.
How many active Wall Street firms cover MDXG?+
5 active firms have a recognized rating on MiMedx Group Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MDXG?+
Among analysts who currently cover MDXG, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #17). Their current call is Buy with a $8.00 target.
What is MiMedx Group Inc's projected EPS for next quarter?+
The consensus estimate is $0.01 per share (range $0.01 – $0.01) across 2 analysts. Full-year EPS is projected at $-0.10, rising to $0.03 the following year.
How much revenue is MiMedx Group Inc expected to report next quarter?+
Consensus revenue is $64.5M (range $62.9M – $65.5M). Full-year revenue is projected at $251.8M, growing to $284.9M next year.
Have analysts been upgrading or downgrading MDXG lately?+
As of Nov 19, 2026, 5 of 5 active firms rate MDXG a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDXG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.